Literature DB >> 16108013

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

Kimio Yonesaka1, Kenji Tamura, Takayasu Kurata, Taroh Satoh, Masato Ikeda, Masahiro Fukuoka, Kazuhiko Nakagawa.   

Abstract

Survivin is a member of the inhibitor of apoptosis protein (IAP) family that is specifically overexpressed in cancer tissues. p53 is one of the tumor suppressor genes; its induction in response to DNA damage causes apoptosis and correlates with drug sensitivity. To investigate the possible regulation of survivin by p53, we examined the level of survivin expression in lung cancer cell lines in response to adriamycin. Levels of survivin mRNA and protein in cell lines with wild-type p53 decreased dramatically after p53 induction, but no such reduction of survivin was observed in cell lines with mutated or null p53. Inhibition of wild-type p53 in A549 cells by small interfering (si) RNA significantly upregulated the expression of survivin. Survivin inhibition by siRNA in PC9 cells with mutated p53 significantly depressed cell proliferation. To investigate the sensitivity of cancer cells to adriamycin after inhibition of survivin, we depressed survivin expression using siRNA, and then added adriamycin at an IC50 dose. After a further 48 hr incubation with adriamycin, proliferation was significantly depressed in the cells treated with siRNA targeting survivin, in comparison with siRNA targeting scramble. Furthermore, both TUNEL and pro-caspase3 expression assay showed a significant increase in apoptosis after combined treatment with adriamycin and siRNA targeting survivin. Our results demonstrate that survivin is downregulated by p53, and that siRNA targeting of survivin increases cell sensitivity to adriamycin and promotes apoptosis. siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16108013     DOI: 10.1002/ijc.21350

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Ubiquitin and SUMO systems in the regulation of mitotic checkpoints.

Authors:  Gustavo J Gutierrez; Ze'ev Ronai
Journal:  Trends Biochem Sci       Date:  2006-05-02       Impact factor: 13.807

2.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

Review 3.  Research progress on Livin protein: an inhibitor of apoptosis.

Authors:  Biao Yan
Journal:  Mol Cell Biochem       Date:  2011-05-27       Impact factor: 3.396

4.  Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.

Authors:  Rebecca A Frum; Ian M Love; Priyadarshan K Damle; Nitai D Mukhopadhyay; Swati Palit Deb; Sumitra Deb; Steven R Grossman
Journal:  Mol Cancer Res       Date:  2016-03-10       Impact factor: 5.852

5.  Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.

Authors:  Y Shao; Y Liu; C Shao; J Hu; X Li; F Li; L Zhang; D Zhao; L Sun; X Zhao; D J Kopecko; D V Kalvakolanu; Y Li; D Q Xu
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

Review 6.  E3 ubiquitin ligases as cancer targets and biomarkers.

Authors:  Yi Sun
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

7.  Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.

Authors:  D J Morrison; L E Hogan; G Condos; T Bhatla; N Germino; N P Moskowitz; L Lee; D Bhojwani; T M Horton; I Belitskaya-Levy; L M Greenberger; I D Horak; S A Grupp; D T Teachey; E A Raetz; W L Carroll
Journal:  Leukemia       Date:  2011-08-16       Impact factor: 11.528

Review 8.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

9.  CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.

Authors:  Elizabeth Tarasewicz; Randala Hamdan; Joelle Straehla; Ashley Hardy; Omar Nunez; Stanislav Zelivianski; Danijela Dokic; Jacqueline S Jeruss
Journal:  Cancer Biol Ther       Date:  2014-07-09       Impact factor: 4.742

10.  Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.

Authors:  Jian-Qing Huang; Hong-Ling Liang; Tian-En Jin; Zhi Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.